Is SNNAQ or XYLD a better dividend investment in 2026?

SNNAQ currently yields 2000000.00% with a 5% 5-year dividend growth rate. XYLD yields 10.98% with 0.5% growth. The better choice depends on your goal: SNNAQ offers higher current income.

What is the dividend yield difference between SNNAQ and XYLD?

SNNAQ has a forward dividend yield of 2000000.00% ($2.00/share annually). XYLD yields 10.98% ($4.30/share annually). The yield gap is 1999989.02 percentage points.

Home › Compare › SNNAQ vs XYLD

SNNAQ vs XYLD: Dividend Comparison 2026

SNNAQ yields 2000000.00% · XYLD yields 10.98%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SNNAQ wins by $1.6247481716182984e+23M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SNNAQ

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1.6247481716182984e+23M

Annual income

$147,608,011,402,949,780,000,000,000,000.00

Full SNNAQ calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

10.98%

Share price

$39.13

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$3,219.02

Full XYLD calculator →

Portfolio growth — SNNAQ vs XYLD

📍 SNNAQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SNNAQ	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SNNAQ + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SNNAQ pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNNAQ

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$125,466,809,692,507,310,000,000,000,000.00/yr

XYLD

Annual income on $10K today (after 15% tax)

$933.63/yr

After 10yr DRIP, annual income (after tax)

$2,736.17/yr

At 15% tax rate, SNNAQ beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNNAQ + XYLD for your $10,000?

SNNAQ: 50%XYLD: 50%

100% XYLD50/50100% SNNAQ

Portfolio after 10yr

$8.123740858091492e+22M

Annual income

$73,804,005,701,474,890,000,000,000,000.00/yr

Blended yield

90.85%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on SNNAQ right now

SNNAQ

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-9.5

Piotroski

2/9

XYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNNAQ buys

XYLD buys

No recent congressional trades found for SNNAQ or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSNNAQXYLD

Forward yield	2000000.00% ✓	10.98%
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	-50%	0% ✓
Portfolio after 10y	$1.6247481716182984e+23M	$25.3K ✓
Annual income after 10y	$147,608,011,402,949,780,000,000,000,000.00 ✓	$3,219.02
Total dividends collected	$1.6146053563276882e+23M	$19.6K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: SNNAQ vs XYLD ($10,000, DRIP)

Year	SNNAQ Portfolio	SNNAQ Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$100,010,700	$100,000,000.00	$10,818	$1,098.39	+$100.00M → SNNAQ
2	$467,446,731,075	$467,339,719,626.17	$11,738	$1,222.51	+$467446.72M → SNNAQ
3	$1,021,215,363,816,662	$1,020,715,195,814,411.90	$12,774	$1,364.64	+$1021215363.80M → SNNAQ
4	$1,043,112,617,104,109,200	$1,042,019,916,664,825,300.00	$13,944	$1,527.86	+$1043112617104.10M → SNNAQ
5	$498,482,143,759,731,400,000	$497,366,013,259,430,040,000.00	$15,270	$1,715.87	+$498482143759731.38M → SNNAQ
6	$111,599,275,650,097,780,000,000	$111,065,899,756,274,860,000,000.00	$16,775	$1,933.09	+$111599275650097776.00M → SNNAQ
7	$11,738,678,336,351,557,000,000,000	$11,619,267,111,405,953,000,000,000.00	$18,490	$2,184.87	+$11738678336351557632.00M → SNNAQ
8	$583,674,362,697,175,100,000,000,000	$571,113,976,877,278,900,000,000,000.00	$20,450	$2,477.63	+$583674362697175072768.00M → SNNAQ
9	$13,894,210,989,607,547,000,000,000,000	$13,269,679,421,521,570,000,000,000,000.00	$22,697	$2,819.19	+$1.3894210989607547e+22M → SNNAQ
10	$162,474,817,161,829,840,000,000,000,000	$147,608,011,402,949,780,000,000,000,000.00	$25,280	$3,219.02	+$1.6247481716182984e+23M → SNNAQ

SNNAQ vs XYLD: Complete Analysis 2026

SNNAQ — Stock

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.

Full SNNAQ Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this SNNAQ vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNNAQ vs SCHD SNNAQ vs JEPI SNNAQ vs O SNNAQ vs KO SNNAQ vs MAIN SNNAQ vs QYLD SNNAQ vs JEPQ SNNAQ vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.